Currently, no medical treatment exists for nonalcoholic steatohepatitis (NASH), inflammation of the liver associated with the accumulation of fat in the liver. Recent studies indicate that NASH can result in scarring of the liver in up to 40 percent of people with the disease and cirrhosis (irreversible, advanced scarring of the liver) in approximately 25 percent of people with NASH. Researchers at Northwestern Memorial Hospital have launched a clinical trial to see if Pentoxifylline, a drug that has shown success decreasing inflammation of the liver in people with alcohol-related liver disease, can stop the progression of NASH.

"NASH is widespread and the number of cases is rising every year it's truly become an epidemic in this country," says Mary Rinella, MD, a hepatologist at Northwestern Memorial Hospital who is the lead investigator of the trial and an assistant professor of Medicine at Northwestern University's Feinberg School of Medicine. "Currently, we don't have anything to offer patients except to advise them to lose weight and change their diet, so many of these patients are ending up on liver transplant waiting lists. We need therapies that help keep people from reaching that point."

In developed countries, the overall prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be approximately 20 percent of the population, with about 3 percent having NASH. NASH differs from the NAFLD, the simple accumulation of fat in the liver, in that the inflammation causes damage to the liver cells while simple fatty liver probably does not. NASH typically occurs in middle-aged, overweight, and often diabetic patients who do not drink alcohol. It has also been connected with rapid weight loss, or in women taking hormones. "Clinical studies and basic research on NAFLD are still in their infancy as compared to other common liver diseases, such as alcoholic liver disease and hepatitis C," says Dr. Rinella. "We didn't really even star
'"/>

Contact: Amanda Widtfeldt
awidtfel@nmh.org
312-926-2955
Northwestern Memorial Hospital
3-Jun-2005

Page: 1 2
Related medicine news :

1. Northwestern chemists develop new method for synthesizing anti-cancer flavonoids
2. $15M Northwestern grant funds heart research
3. Northwestern surgeon invents teaching technology for scary patient exams
4. Northwestern Memorial earns magnet status for nursing excellence
5. Heart transplant program at Northwestern Memorial Hospital celebrates anniversary
6. Evanston Northwestern Healthcare first to use latest robotic surgical system
7. Northwestern researchers launch Avastin trial for pancreatic tumors
8. Northwestern Memorial Hospital named Bariatric Surgery Society Center of Excellence
9. Northwestern receives major award for nanotechnology cancer center
10. Northwestern Memorial named one of 100 Best Places for Working Mothers
11. Northwestern Memorial named among 100 Most Wired Hospitals for sixth consecutive year